We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




Fecal Analyses Leads to Inflammatory Bowel Disease Diagnosis

By LabMedica International staff writers
Posted on 23 Feb 2016
Print article
The Clarus 500 gas chromatography mass spectrometry (GC-MS)
The Clarus 500 gas chromatography mass spectrometry (GC-MS) (Photo courtesy of Perkin Elmer)
The development of sophisticated analytical techniques has enabled the study and interpretation of changes in the fecal volatile organic metabolites and its correlation with the pathophysiological mechanisms in the gut during health and disease.

The etiology of inflammatory bowel disease (IBD) remains poorly understood, but recent evidence suggests an important role of gut microbial dysbiosis (also called dysbacteriosis, a term for a microbial imbalance on or inside the body) in IBD, and this may be associated with changes in fecal volatile organic metabolites (VOMs).

Gastroenterologists at the University Hospital Southampton (UK) and their colleagues obtained fecal samples from 117 people with Crohn's disease (CD), 100 with ulcerative colitis (UC), and 109 healthy controls. Fecal VOMs were extracted using solid-phase micro-extraction and analyzed by gas chromatography mass spectrometry. Data analysis was carried out using partial least squares-discriminate analysis (PLS-DA) to determine class membership based on distinct metabolomic profiles.

Fecal samples were submitted within six hours of bowel movement. A 2-gram aliquot was placed into 18-mL headspace vial (Supelco; Poole, UK). The VOMs were thermally desorbed by immediately transferring the fiber into the heated injection port (220 °C) of a Clarus 500 gas chromatography mass spectrometry (GC-MS, PerkinElmer; Beaconsfield, UK). The GC-MS generated a chromatogram with peaks representing individual compounds.

The scientists used the PLS-DA model to show clear separation of active CD from inactive disease and healthy controls. Heptanal, 1-octen-3-ol, 2-piperidinone and 6-methyl-2-heptanone were up-regulated in the active CD group [variable importance in projection (VIP) score 2.8, 2.7, 2.6 and 2.4, respectively], while methanethiol, 3-methyl-phenol, short-chain fatty acids and ester derivatives were found to be less abundant (VIP score of 3.5, 2.6, 1.5 and 1.2, respectively). The PLS-DA model also separated patients with small bowel CD from healthy controls and those with colonic CD from UC. In contrast, less distinct separation was observed between active UC, inactive UC and healthy controls.

The authors concluded that analysis of fecal volatile organic metabolites can provide an understanding of gut metabolomic changes in IBD. It has the potential to provide a noninvasive means of diagnosing IBD, and can differentiate between UC and CD. New studies indicates that analyses of vapors from fecal samples can identify volatile metabolites indicative of different types of inflammatory bowel disease, including Crohn's disease and ulcerative colitis. The study was published online on January 25, 2016, in the journal Alimentary Pharmacology & Therapeutics.

Related Links:

University Hospital Southampton
Supelco
PerkinElmer 


New
Gold Member
Rotavirus Test
Rotavirus Test - 30003 – 30073
Verification Panels for Assay Development & QC
Seroconversion Panels
New
Biological Indicator Vials
BI-O.K.
New
Respiratory QC Panel
Assayed Respiratory Control Panel
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get complete access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Molecular Diagnostics

view channel
Image: Researcher Kanta Horie places a sample in a mass spectrometer that measures protein levels in blood plasma and other fluids (Photo courtesy of WashU Medicine)

Highly Accurate Blood Test Diagnoses Alzheimer’s and Measures Dementia Progression

Several blood tests are currently available to assist doctors in diagnosing Alzheimer's disease in individuals experiencing cognitive symptoms. However, these tests do not provide insights into the clinical... Read more

Immunology

view channel
Image: The findings were based on patients from the ADAURA clinical trial of the targeted therapy osimertinib for patients with NSCLC with EGFR-activated mutations (Photo courtesy of YSM Multimedia Team)

Post-Treatment Blood Test Could Inform Future Cancer Therapy Decisions

In the ongoing advancement of personalized medicine, a new study has provided evidence supporting the use of a tool that detects cancer-derived molecules in the blood of lung cancer patients years after... Read more

Microbiology

view channel
Image: Schematic representation illustrating the key findings of the study (Photo courtesy of UNIST)

Breakthrough Diagnostic Technology Identifies Bacterial Infections with Almost 100% Accuracy within Three Hours

Rapid and precise identification of pathogenic microbes in patient samples is essential for the effective treatment of acute infectious diseases, such as sepsis. The fluorescence in situ hybridization... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.